|Serotonin and norepinephrine reuptake inhibition with effects on multiple receptor systems and sodium conductance.|
|(e.g., amitriptyline, imipramine)|
|Selective serotonin reuptake inhibitorsb|
|(e.g., fluoxetine, sertraline, paroxetine, fluxamine)|
|Selective norepinephrine reuptake inhibitorsb|
|(e.g., desiptamine, maprotiline)|
|Serotonin and norepinephrine reuptake inhibitors|
|Serotonin (5-HT2A) receptor blockade with serotonin reuptake inhibition|
|Serotonin (5-HT2A and 2C) receptor blockade with norepinephrine (alpha-2) receptor blockade|
|Dopamine and norepinephrine reuptake inhibition|
|Monoamine oxidase inhibitors|
|(e.g., tranycypromine, phenelzine, isocarboxazid)d|
a Although the pathophysiology of depression remains unclear, drugs are classified by prominent mechanism(s) of action believed to mediate antidepressant efficacy.
b The selectivity may be obscured at doses higher than those recommended for routine treatment of depression.
c Both nefazodone and mirazipine have additional non-antidepressant mechanisms of action which are engaged at concentrations that occur under clinically relevant dosing guidelines.
d Only irreversible/nonselective monoamine oxidase inhibitors (MAOIs) are marketed in the United States, but reversible/selective MAOIs are marketed elsewhere in the world and are in development.
Back to Chapter